logo
Plus   Neg
Share
Email

Celgene: Oral OTEZLA Shows Long-Term Benefits For Active Psoriatic Arthritis

Celgene International Sàrl, an unit of Celgene Corp. (CELG), reported results of additional analyses from the phase III trials of OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 or PDE4. These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1.

"People with psoriatic arthritis live with persistent symptoms of this painful disease," said Georg Schett, director of the Department of Internal Medicine III - Rheumatology and Immunology, University Hospital Erlangen, Germany. "These analyses of one-year data from the PALACE trials suggest that, based on the efficacy and safety data we've seen to-date, OTEZLA has the potential to help patients for the long-term management of manifestations of their psoriatic arthritis," he added.

The long-term (52-week) results from three trials showed that treatment with OTEZLA improved measures of psoriatic arthritis disease activity, including tender and swollen joints, compared with placebo at 16 weeks.

Long-term safety results from an analysis of pooled data from the PALACE 1, 2 and 3 trials identified no new safety findings for patients with psoriatic arthritis who were treated with OTEZLA for up to 52 weeks, compared with the previously reported 24-week safety results.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT